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Abstract
MicroRNAs (miRNAs) are small noncoding RNAs that negatively regulate gene expression post-transcriptionally. They play a
critical role in developmental and physiological processes and have been implicated in the pathogenesis of several diseases
including cancer. To identify miRNA signatures associated with different stages of neoplastic development, we examined
the expression profile of 776 primate miRNAs in VERO cells (a neoplastically transformed cell line being used for the
manufacture of viral vaccines), progenitor primary African green monkey kidney (pAGMK) cells, and VERO cell derivatives:
spontaneously immortalized, non-tumorigenic, low-passage VERO cells (10-87 LP); tumorigenic, high-passage VERO cells
(10-87 HP); and a cell line (10-87 T) derived from a 10-87 HP cell tumor xenograft in athymic nude mice. When compared
with pAGMK cells, the majority of miRNAs were expressed at lower levels in 10-87 LP, 10-87 HP, and 10-87 T cells. We
identified 10 up-regulated miRNAs whose level of expression correlated with VERO cell evolution from a non-tumorigenic
phenotype to a tumorigenic phenotype. The overexpression of miR-376a and the polycistronic cluster of miR-376a, miR-
376b and miR-376c conferred phenotypic changes to the non-tumorigenic 10-87 LP cells that mimic the tumorigenic 10-87
HP cells. Thirty percent of miRNAs that were components of the identified miRNAs in our spontaneously transformed AGMK
cell model are also dysregulated in a variety of human tumors. These results may prove to be relevant to the biology of
neoplastic development. In addition, one or more of these miRNAs could be biomarkers for the expression of a tumorigenic
phenotype.
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Introduction
Neoplastic development represents cumulative genetic and
epigenetic events leading to the emergence of cells that can attain
a tumorigenic phenotype [1,2,3,4]. Neoplastic transformation of
cells cultured in vitro can be induced by several methods, such as
treatment with chemical carcinogens or radiation, viral infection,
or the introduction of oncogenes [1,2,5]. To help understand how
tumors originate and progress in mammals, cells transformed in
vitro by these methods have been used for many years to study
processes analogous to neoplastic development in vivo.
Cells from non-human mammalian species, in the absence of
known carcinogenic stimuli, can spontaneously undergo processes
of neoplastic transformation during culture in vitro. It is well
documented that repeated passage of cells in culture can result in
their immortalization and can lead to the acquisition of the
capacity to form tumors when injected into animals [6,7]. The
neoplastically transformed VERO cell line, which was derived
from primary African green monkey kidney (pAGMK) cells [8]
and is used in diagnostic virology and for the manufacture of viral
vaccines, is known for its propensity to develop the capacity to
form tumors following prolonged in vitro passage [9,10,11,12]. In
our studies, we have shown that the 10-87 VERO cell line was
non-tumorigenic at low passage [passage (p) 148] when injected
into athymic nude mice. However, when these cells were serially
passaged in culture to higher passage levels (p256), they were
found to be tumorigenic when injected into newborn nude mice
[11]. Thus, the neoplastic processes that occur spontaneously in
VERO cells in culture, resulting in cells that express a tumorigenic
phenotype, offer an opportunity to evaluate the molecular
differences that may underlie the different stages of neoplastic
development in vitro.
Recently, it has become evident that, in addition to mutation of,
and/or changes in, the expression of protein-coding genes,
alterations in the expression of non-coding microRNAs (miRNAs)
can also contribute to cancer pathogenesis [13,14,15,16]. miRNAs
modulate gene expression at the post-transcriptional level by
inducing either degradation of the mRNA transcript or transla-
tional repression [17]. Many of the genes for these targeted
mRNAs are involved in proliferation, differentiation, and
apoptosis [13,14,15,17,18,19], processes that are frequently
altered during neoplastic development. Indeed, it has been shown
that dysregulation of miRNA expression can contribute to cellular
transformation and tumorigenesis [13,14,20]. To identify the
miRNAs involved in these processes, a number of studies have
compared miRNA expression profiles of various tumors with those
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that alterations in miRNA expression profiles can serve as
molecular signatures of particular types of cancer. Importantly,
miRNA expression profiles appear to be more informative than
mRNA expression profiles in reflecting the developmental lineage
and the differentiation state of tumors [20,22]. Furthermore,
profiling of miRNA expression can identify miRNAs that might
serve as diagnostic and prognostic markers for different cancers as
well as potential therapeutic targets [23,24,25,26,27]. Based on the
pleiotropic effects of miRNAs in neoplastic development, we
hypothesized that the molecular events that occurred during serial
passage of pAGMK cells in tissue culture that led to immortal-
ization and then to the expression of a tumorigenic phenotype
might be associated with progressive alterations of cellular miRNA
regulatory networks analogous to those observed in neoplastic cells
arising in vivo.
In this report, we performed high-throughput miRNA
profiling to examine the expression level of miRNAs in pAGMK
cells and in VERO cells at non-tumorigenic and tumorigenic
stages of neoplastic development. The analysis involved (1)
pAGMK cells, (2) non-tumorigenic 10-87 low-passage VERO
cells (10-87LP), (3) tumorigenic, high-passage VEROcells(10-87
HP), and (4) a cell line (10-87 T) derived from a 10-87 HP cell
tumor xenograft in athymic nude mice. Our data revealed that,
although some miRNA dysregulation occurred during the
immortalization of the AGMK cells that established the VERO
cell line, the majority of miRNA dysregulation occurred in
VERO cells during the transition from a non-tumorigenic to a
tumorigenic phenotype. We identified the up-regulation of
specific miRNAs that correlated with, and were perhaps involved
in, the evolution of the neoplastic phenotype that occurred
during serial passage of VERO cells in culture. Indeed, the
overexpression of miR-376a and the polycistronic cluster of miR-
376a, miR-376b and miR-376c in non-invasive 10-87 LP cells
were able to recapitulate the migration and invasion phenotypes
of 10-87 HP cells. Cumulatively, these data suggest that the
patterns of dysregulation of the miRNAs identified in this study
might be a feature of neoplastic development in vitro in kidney
cells from this non-human primate.
Results
In vitro cell migration and invasion activities of VERO cell
lines
The 10-87 VERO cell lines used in this study were derived from
the World Health Organization (WHO) VERO cell bank (10-87)
after serial passage in tissue culture from p140 to p256 [11]. The
non-tumorigenic 10-87 LP cells (p148), the tumorigenic 10-87 HP
cells (p256), and the VERO tumor cell line 10-87 T, which was
derived from a tumor xenograft formed by the inoculation of 10-
87 HP cells into newborn athymic nude mice [11], were selected
for study. The characteristics of the cell lines used in this study are
summarized in Table 1.
Survival, proliferation, invasion, and migration are among the
common functions acquired by cancer cells during neoplastic
development [28,29,30,31]. To initiate the characterization of our
AGMK cell lines, and to evaluate the impact of serial passage on
proliferation, invasion, and migration, we compared the different
VERO cell lines by cell-growth rates, wound-healing migration
assays, and invasion assays. The growth rates (cell doubling times)
of the 10-87 cells were comparable, indicating that serial passage
did not affect the rate of cell proliferation in these cells (Table 1).
The wound-healing assay measures cell migration/motility in vitro.
Figure 1A shows representative photomicrographs taken of
wounded cell-culture monolayers at 0 and 12 h after the
monolayer surfaces were scratched. The 10-87 HP cells and 10-
87 T cells displayed an increase in migration compared with 10-87
LP cells. Little or no motility was observed in 10-87 LP cells during
this observation period, whereas the 10-87 HP cells and 10-87 T
cells started to fill in the wound as early as 9 h (data not shown). In
the invasion assay, the Matrigel matrix serves as a barrier to
distinguish between invasive cells and non-invasive cells. In this
assay, the relative migration of cells from the upper chamber to the
lower chamber compared with a reference cell line (non-
tumorigenic 10-87 LP) provides an invasion index. We found
that 10-87 HP cells and 10-87 T cells had a more than four-fold
increase in invasiveness over 10-87 LP cells (Fig. 2A).
The above results suggested: first, 10-87 LP cells had already
attained the proliferative potential expressed by 10-87 HP and
Table 1. Growth rates and tumorigenic characteristics of the cell lines used for miRNA studies.
Cell Line
(passage level) Doubling Time (h)
1 Tumor Incidence in Nude Mice Reference
Newborns Adults
10-87 LP (p148) 25 0/17
2 0/14
2 [11]
10-87 HP (p256) 26 16/30
2 0/18
2 [11]
10-87 T 25 ND ND [11]
A4497 (p165) 18 0/4
2 2/25
2 [11]
A4497 (p.200) ND 12/13 6/10 [11]
SF- VERO 20 9/17
2 4/17
2 [11]
CV-1 (p40) 27 0/7
3 0/10
3
BSC-1 (p49) 30 0/15
3 0/10
3
1Cells (5610
4) were seeded in 60-mm dishes, and viable cell numbers were determined in triplicate by trypan-blue exclusion after 16, 24, 48, and 72 h. Cell-doubling
times were estimated from growth-curve plots.
2Observation period was 1 year in adult and newborn nude mice.
3Newborns have been observed for .8 months and adults have been observed for 1 year.
ND: not determined.
doi:10.1371/journal.pone.0014416.t001
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tissue culture beyond the 10-87 LP p140 level resulted in the
acquisition of the potential to migrate and invade; third,
migration and invasion phenotypes of 10-87 HP and 10-87 T
cells appeared to correlate with their ability to form tumors in
vivo.
Figure 1. Wound-healing assay using African green monkey kidney cell lines. (A) 10-87 LP, 10-87 HP and 10-87 T. (B) BSC-1, CV-1, SF-VERO,
and A4497 (p165). Microscopic observations were recorded at 0, 6, 9, and 12 h after scratching the cell surface; the 0 and 12 hour images are shown.
doi:10.1371/journal.pone.0014416.g001
Figure 2. Matrigel-invasion assay with African green monkey kidney lines. (A)10-87 HP and 10-87 T; (B) BSC-1, CV-1, SF-VERO, and A4497.
The cells were placed in a Matrigel-invasion chamber, and cells that invaded the Matrigel were fixed, stained, and counted. Test and control (10-87 LP)
cells that invaded the Matrigel were counted in 5 fields under a 206objective. The data were expressed as fold percent invasion of 10-87 LP cells. The
mean data are plotted with their standard deviations.
doi:10.1371/journal.pone.0014416.g002
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different phenotypes
The dysregulation of miRNA expression has been observed in cells
obtained from various cancers [13,20,22]. Because the serial passage of
VERO cells results in the acquisition of a tumorigenic phenotype [11],
we evaluated whether miRNA expression could be correlated with the
evolution of the neoplastic processes that were occurring in VEROcells
during serial tissue-culture passage. Array-based miRNA profiling was
performed on pAGMK cells and on non-tumorigenic and tumorigenic
VERO cells. For each cell type, the analysis was performed in
triplicate. Out of 776 primate miRNAs assayed, 654 were detected
above background levels in at least 3 of the 12 datasets. When
unsupervised hierarchical clustering analysis was done on the 654
miRNAs expressed in pAGMK cells, 10-87 LP cells, 10-87 HP cells, or
10-87 T cells, the miRNA tree generated was able to discriminate
among all four types of cells, with pAGMK cells located at a distance
from the clusters of the three VERO cell line derivatives (data not
shown). ANOVA was done using the four cell types. All significantly
expressed miRNAs with mean intensity values of more than 500
(arbitrary units) in at least in one of the four cell types and a p,0.01
were selected and transformed to z-intensity values for inclusion in the
heat-maps. These miRNAs were regarded as significant and were
considered to be differentially expressed (Fig. 3). Four distinct clusters of
miRNAs were evident according to their similar expression patterns.
The expression profile of miRNA in cluster-I indicated a general up-
regulation in tumorigenic 10-87 HP cells and 10-87 T cells compared
with pAGMK cells and 10-87 LP cells. Clusters-II,-III, and -IV
contained miRNAs that were down-regulated in 10-87 HP cells and
10-87 T cells.Expression readoutsofthemiRNAarrays weresubjected
to paired, volcano-plot analysis to arrive at differences of means for
each miRNA in 10-87 LP cells compared with 10-87 HP cells and 10-
87 T cells, and 10-87 HP cells compared with 10-87 T cells. The
analysis revealed distinct patterns of miRNA expression that
distinguished the non-tumorigenic 10-87 LP cells from the tumorigenic
10-87 HP cells and 10-87 T cells (data not shown). When this
comparison was performed between the miRNA expression profiles of
10-87 HP cells and 10-87 T cells, no significant differences were
apparent (Table 2). These observations indicated that the dysregulation
of miRNA expression during in vitro passaging correlated with the
conversion of 10-87 LP cells to a tumorigenic phenotype at higher
passage levels. Furthermore, no additional dysregulation of miRNA
expression appeared to occur during tumor formation.
Identification of differentially expressed miRNAs
The next step was to identify miRNAs that were differentially
expressed between pAGMK and either non-tumorigenic or
tumorigenic VERO cells. Since it is likely that pAGMK cells are
representative of the normal diploid precursor cell type that gave
rise to VERO cells, they can serve as a baseline to identify the
alterations in miRNA expression that occurred during serial
passage of VERO cells in tissue culture. When comparing two
groups, findings were considered significant if: (1) fold change was
$4 relative to levels observed in pAGMK cells; (2) t-test p-value
was ,0.01, and (3) differences in fluorescence intensity between
the means of two groups were .500 arbitrary units. The
stringency was set at $4 fold with the intent of identifying the
smallest number of miRNAs with the highest probability of
contributing to VERO cell neoplastic development. Using these
criteria, we identified 10 upregulated and 17 downregulated
miRNAs in 10-87 HP cells (Table 2). The differentially expressed
miRNAs in 10-87 T cells were the same as those in 10-87 HP cells.
The 10 miRNAs that were down-regulated in 10-87 LP cells
relative to pAGMK cells were a sub-set of the miRNAs whose
expression was also down-regulated in the 10-87 HP cells and 10-
87 T cells (Table 2). The magnitude of change in expression levels
for these miRNAs was greater in 10-87 HP cells and 10-87 T cells
when compared with 10-87 LP cells, demonstrating a progressive
alteration of miRNA expression during serial passage of 10-87 LP
cells and suggesting that their changed expression may be related
to the acquisition of the new phenotype.
Validation of miRNA expression
In order to validate the miRNA microarray data for VERO
cells at the passage levels tested, we performed qRT-PCR analysis
to quantify the expression level of selected miRNAs from a list of
differentially expressed miRNAs. The data are presented as fold
over pAGMK miRNA levels (Table 3). qRT-PCR analysis
confirmed that miR-376a, miR-654-3p, miR-543, miR-382,
miR-31, miR-200c, miR-218, and miR-183 paralleled the
microarray miRNA levels. Included as controls were two miRNAs,
miR-103 and miR-25, whose microarray expression levels were
not statistically different in cell lines with different phenotypes.
These miRNAs also showed no significant differences by qRT-
PCR in 10-87 LP cells, 10-87 HP cells, and 10-87 T cells. These
qRT-PCR results demonstrated that the microarray analysis
accurately reflected expression levels of the miRNAs.
miRNA expression patterns correlated with the level of
neoplastic progression in other AGMK cell lines
The results above raised the question of whether the observed
miRNA expression signature in 10-87 HP and 10-87 T cells was
specific to this VERO lineage or was a more general phenomenon
that might be associated with the acquisition of tumorigenic
phenotypes by other cell lineages derived from the VERO cell line
as well as from other immortalized AGMK cell lines. To address
this question, we extended the qRT-PCR expression analysis of
selected miRNAs to SF-VERO cells, a tumorigenic line of VERO
cells adapted to grow in serum-free medium, and to A4497 VERO
cells, a tumorigenic line of VERO cells developed independently
of 10-87 VERO cells at the National Institutes of Health (Table 1).
When the ability of the SF-VERO and A4497 VERO cell lines to
migrate and invade in the in vitro assays was compared, a close
similarity with the behavior of 10-87 HP cells was observed in the
migration assay (Fig. 1B) and in the invasion assay (Fig. 2B). To
determine if the similar phenotypes correlated with similar
alterations in miRNA expression in these cell lines, a qRT-PCR
analysis was done on the selected miRNAs (based on $4-fold
changes at p,0.01). As found for 10-87 HP cells and 10-87 T cells,
SF-VERO cells and A4497 VERO cells expressed increased levels
of miR-376a, miR-654-3p, miR-543, and miR-382 over the levels
found in pAGMK cells (Table 4). Similarly, the miRNAs down-
regulated in 10-87 HP cells and 10-87 T cells, such as miR-31,
miR-200c, miR-218, and miR-183, were also found to be down-
regulated in A4497 VERO cells and SF-VERO cells.
We next evaluated the non-tumorigenic CV-1 and BSC-1 cell
lines (Table 1) for their cell-growth rates, their wound-healing and
invasion characteristics, and their patterns of expression of the
same selected miRNAs. These cell lines were independently
derived from pAGMK cells [32,33] and have no lineage
relationship to VERO cells. Similar to 10-87 LP cells, CV-1 and
BSC-1 cells exhibited limited motility and invasiveness (Fig. 1B
and Fig. 2B, respectively). In contrast to 10-87 LP cells, the
expression patterns of the selected miRNAs in CV-1 and BSC-1
cell lines were somewhat variable. The expression levels of the
miRNAs in CV-1 cells were similar to those in 10-87 LP cells;
however, the upregulated miRNA expression levels in BSC-1 cells
were slightly higher than those exhibited by 10-87 LP cell and
slightly lower than those exhibited by A4497 cells at p165, placing
miRNA and Neoplasia In Vitro
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trend in selected miRNA expression by the different AGMK
lineages positioned between CV-1 and SF-VERO cells appeared
to correlate with the progressive stages of neoplastic development
that result in the expression of the tumorigenic phenotype.
miRNA over-expression promotes cell migration and
invasion
To determine whether the overexpression of the identified
signature miRNAs could confer phenotypic changes, stable cell
lines were created by cloning the pre-miRNA sequences of miR-
376a, miR-376abc, miR-299, or miR-382 into the pcDNA6.2-
GW/EmGFP-miR vector, which contains a green fluorescent
protein (GFP) cassette, and introducing them into the non-
tumorigenic 10-87 LP cells. We confirmed the expression of each
of the miRNAs in their stable cell lines by qRT-PCR. The
consequence of miRNA over-expression on the phenotype of the
10-87 LP cells was assessed in the wound-healing and the
Matrigel-invasion assays. In the former assay, photomicrographs
were taken of wounded cell-culture monolayers at time 0 and at
every 3 h up to 15 h to determine the effect of overexpression of
the miRNAs on the rate of migration. Only photomicrographs at 0
Figure 3. Hierarchical clustering of miRNA expression. miRNAs included in the heat-map had a fold change .62 and were significantly
expressed (p,0.01). Each row shows the relative expression level for a single miRNA and each column represents miRNA profiles of the average
triplicate array data: (1) pAGMK cells; (2) 10-87 LP cells; (3) 10-87 HP cells; (4) 10-87 T cells. The red or green color indicates relative high or low
expression, respectively. Expression clusters representing different patterns of up-regulation to down-regulation are depicted by Roman numerals on
the right hand side of the Figure.
doi:10.1371/journal.pone.0014416.g003
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miR-376abc displayed an increase in migration compared with
control 10-87 LP cells. However, little or no migration was
observed for cells expressing miR-299 or miR-382. In agreement
with the wound-healing assay, over-expression of miR-376a or
miR-376abc also resulted in more than a four-fold increase in
invasiveness, whereas miR-299 or miR-382 had no effect (Fig. 4B).
The miRNA effect was specific, as we found no change in
migration or invasion ability of cells expressing irrelevant miRNA
(miR-control) in 10-87 LP cells. These results demonstrated that
over-expression of some of the identified signature miRNAs were
able to confer the migration and invasion phenotypes of 10-87 HP
cells to 10-87 LP cells.
Chromosomal location of differentially expressed
miRNAs
Using the Sanger miRNA database, we examined the
chromosomal distribution of miRNAs that were altered in 10-87
LP and 10-87 HP cells. miRNA genes are frequently located in
cancer-associated regions of the human genome [34], and
alterations of chromosomal regions containing miRNAs have
Table 2. Differentially expressed mature miRNAs in low-passage and high-passage VERO cells in comparison with pAGMK cells.
Name a 10-87 LP 10-87 HP 10-87 T Chromosomal location
FC p-value (t-test) FC p-value (t-test) FC p-value (t-test) Human Rhesus
miR-376a - - 8.1 2.35E-03 8.1 2.13E-03 14 7
miR-654-3p - - 7.1 2.08E-03 6.9 1.97E-03 14 7
miR-376c - - 6.6 2.08E-03 6.6 1.87E-03 14 7
miR-369-3p - - 6.3 4.65E-04 6.1 1.27E-03 14 7
miR-543 - - 5.8 6.50E-04 5.6 1.14E-03 14 7
miR-376b - - 5.8 6.39E-03 8.4 1.19E-03 14 7
miR-494 - - 4.7 4.67E-03 4.7 4.73E-03 14 7
miR-299-5p - - 4.5 3.68E-03 4.6 4.17E-03 14 7
miR-382 - - 3.6 6.59E-03 3.7 6.29E-03 14 7
miR-134 - - 3.2 3.82E-03 3.4 2.83E-03 14 7
miR-923 - - -2.2 4.47E-03 22.1 1.03E-03 17 ?
miR-374b - - 22.2 7.04E-03 22.2 4.19E-03 X X
miR-342-3p - - 22.2 2.98E-03 22.2 4.39E-03 14 7
miR-200b - - 22.3 8.53E-04 23.3 2.39E-02 1 ?
miR-671-5p -2.1 2.96E-03 22.7 6.32E-03 22.9 5.79E-03 7 3
miR-10b - - 24.0 6.93E-03 24.3 4.32E-03 2 12
miR-125b - - 23.7 4.86E-03 22.9 5.08E-03 11 14
miR-100 - - 23.8 4.13E-03 22.8 7.58E-03 11 14
miR-10a 22.7 4.54E-03 25.6 5.23E-03 25.5 1.55E-03 17 16
miR-638 23.4 1.24E-04 25.4 2.58E-04 24.7 1.16E-03 19 19
miR-150 24.9 1.55E-05 25.8 1.76E-03 25.8 4.98E-04 19 19
miR-149 24.3 6.52E-07 26.0 5.83E-03 25.7 6.07E-03 2 12
miR-371-5p 25.1 1.64E-03 26.8 8.13E-04 26.5 1.04E-03 19 19
miR-663 25.2 3.58E-07 26.9 5.74E-05 26.6 2.59E-03 20 20
miR-218 26.9 9.04E-04 27.0 1.17E-03 27.2 9.22E-04 4 1
miR-200c 25.4 7.13E-08 28.0 1.33E-04 28.1 1.18E-03 12 11
miR-31 28.4 5.51E-11 29.6 2.07E-04 29.4 1.19E-04 9 15
FC: Fold change (log2) over pAGMK cells.
aonly miRNAs that meet the criteria of being at least 4-fold up- or down-regulated with p,0.01.
doi:10.1371/journal.pone.0014416.t002
Table 3. Validation of the differential expression of selected
miRNA in 10-87 VERO cells using Taqman quantitative RT-
PCR
1.
miRNA 10-87 LP 10-87 HP 10-87 T
miR-376a 2.2 27.7 24.6
miR-654-3p 1.8 17.8 8.9
miR-543 2.5 23.1 22.0
miR-382 1.2 10.3 10.9
miR-31 2435.0 2500.0 2625.0
miR-200c 218.0 218.7 225.2
miR-218 233.0 220.0 225.0
miR-183 25.0 29.1 28.3
miR-103 1.0 1.1 1.0
miR-25 1.0 1.0 1.0
1Results from the triplicate samples were averaged following normalization to
the levels of small RNA U6B. The data were presented as fold change over
pAGMK miRNA levels.
doi:10.1371/journal.pone.0014416.t003
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the genome of the African green monkey is not complete, we used
the rhesus monkey as a guide to examine the chromosomal
distribution of the differentially expressed miRNAs. A pattern
emerged when the chromosomal location of the genes for those
miRNA whose expression was altered in the 10-87 HP cells was
determined. The 10 miRNA genes whose expression was up-
regulated (Table 2) were clustered within a 47.6 kb region on the
rhesus macaque chromosome 7. This chromosomal region is
homologous to human chromosomal region 14q32.31, which can
be found altered in some human tumors [37,38]. The panel of the
776 miRNAs screened in this study included other miRNAs whose
genes are also located in this region, such as miR-300 and miR-
541, but their expression was not modulated with passage of
VERO cells. The 10-87 HP VERO cells were also characterized
by the down-regulation of 17 miRNAs. For these miRNAs, no
clustering of their genes with a specific chromosomal location was
observed (Table 2).
Discussion
Dysregulation of miRNA expression has been linked to the
formation and progression of many types of cancers
[13,16,37,39,40,41,42,43]. A number of studies have shown that
profiles of miRNA expression can serve as phenotypic signatures
of different cancer types. For example, analysis of a panel of more
Table 4. The expression patterns of selected miRNA in other
AGMK cells using Taqman quantitative RT-PCR
1.
miRNA CV-1 BSC-1
A4497
p165
A4497
p.200 SF-VERO
miR-376a 1.0 3.8 10.8 28.3 52.8
miR-654-3p 1.3 4.9 10.2 32.4 20.2
miR-543 1.4 10.6 8.9 34.1 27.9
miR-382 1.0 2.2 4.1 ND 12.2
miR-31 265.0 265.0 2290.0 21942.0 2345.0
miR-200c 21.5 21.3 28.8 210.0 210.3
miR-218 23.4 21.0 210.0 219.8 26.7
miR-183 25.9 25.5 25.3 22.2 233.0
miR-103 1.0 1.2 1.0 -2.2 1.0
miR-25 1.0 1.0 1.0 1.6 1.1
1Results from the triplicate samples were averaged following normalization to
the levels of small RNA U6B. The data were presented as fold change over
pAGMK miRNA levels.
ND: not determined.
doi:10.1371/journal.pone.0014416.t004
Figure 4. Correlations of over-expression of miRNA with migration and invasive phenotypes. (A) Wound-healing assay of stably
expressing miR-376a, miR376abc (a polycistronic cluster of miR-376a, miR-376b and miR-376c), miR-299-5p or miR-negative and 10-87 LP cells; (B)
Matrigel-invasion assay with stably expressing miR-376a, miR-376abc, miR-299-5p or miR-negative 10-87 HP cells. 10-87 LP cells were used as the
control in the computation of the invasion index.
doi:10.1371/journal.pone.0014416.g004
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samples indicated that miRNA profiles reflected the developmen-
tal lineage and differentiation status of this neoplasm [20]. A
similar study that involved analysis of 540 solid tumors identified
miRNA signatures composed largely of over-expressed miRNAs
[44]. In addition, miRNA expression profiling of 60 cancer-
derived cell lines (NCI-60 cell lines) allowed the clustering of the
cell lines according to their tissue of origin and identified specific
miRNAs in different tumor types as candidate oncogenes and
tumor-suppressor genes [45]. Another recent study identified
miRNA expression patterns that appeared to be associated with
steps during in vivo neoplastic development in a mouse pancreatic
tumor model [46]; this study found that miRNA profiling can be
employed to detect miRNA dysregulation at different stages of
neoplastic progression in vivo (hyper-proliferation, angiogenesis,
primary tumor, and metastasis).
Reported here are the results of the first miRNA expression-
profiling study of non-human primate cells that transformed
spontaneously during serial passage in cell culture. We evaluated
patterns of miRNA expression in pAGMK cells and in derivatives
of the 10-87 VERO cell line (10-87 LP cells, 10-87 HP cells, and
10-87 T cells) in an attempt to identify the miRNAs whose altered
expression might correlate with, and perhaps be involved in, the
evolution of the neoplastic phenotypes that occurred during
passage of these AGMK cells in tissue culture. Hierarchical
clustering of miRNA expression profiles revealed that many
miRNAs were differentially expressed in the tumorigenic 10-87
HP cells and tumor-derived 10-87 T cells when compared with
pAGMK cells. In contrast, fewer miRNAs were differentially
expressed when the non-tumorigenic 10-87 LP cells were
compared with pAGMK cells. These results suggested that the
dysregulation of the majority of miRNAs occurred in the 10-87
cell lineage during the transition from a non-tumorigenic to a
tumorigenic phenotype. Furthermore, when the expression levels
of the up-regulated miRNAs were organized according to their cell
line-determined expression patterns, a correlation emerged
between the relative expression (compared with levels in pAGMK
cells) of representative miRNAs and the evolution of the 10-87
VERO cells into cells that could form tumors in nude mice (Fig. 5).
From this correlation, we suggest that a sequence of changes in
miRNA expression occurred during the tissue-culture passage-
induced neoplastic transformation of 10-87 VERO cells. The
initial changes in miRNA expression, which appear to be
associated with the initiation of neoplastic development and cell
immortalization, occurred prior to p148 (a passage level at which
10-87 LP cells were shown to be non-tumorigenic). These initial
changes consisted of the down-regulation of multiple miRNAs,
highlighted by the down-regulation of miR-31, miR-200c, and
miR-218. The up-regulation of specific miRNAs occurred
between p148 and p256 (Table 3); p256 was a passage level at
which 10-87 HP cells expressed the ability to form tumors in
newborn nude mice. The miRNA-expression patterns obtained
from immortalized non-tumorigenic CV-1 cells and BSC-1 cells
and the tumorigenic A4497 VERO cells at p165 supported the
evolving increase in miRNA expression found between 10-87 LP
cells at p148 and 10-87 HP cells at p256 (Fig. 5). In contrast, the
Figure 5. Correlation between expression of miRNAs and the neoplastic phenotype. The qRT-PCR values of over-expressed miRNAs
(Table 3) were used to locate on the X-axis the position of seven lines of immortalized AGMK cells relative to pAGMK cells. Based on the relative
magnitude of the expression levels of these miRNAs compared with their expression levels in pAGMK cells, the non-tumorigenic CV-1 cells were the
closest and the tumorigenic SF-VERO cells were the most distantly removed from pAGMK cells (the reference point for the non-tumorigenic
phenotype). When the in vitro and in vivo characteristics of all cells were superimposed, the trend in miRNA expression in the different AGMK lineages
between CV-1 and SF-VERO cells on the X-axis appears to correlate with both the passage level in tissue culture and the evolution of the neoplastic
process. The phenotypes were deduced from Table 1 and the data from the invasion assays.
doi:10.1371/journal.pone.0014416.g005
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appear to correlate with the change in VERO cells to a
tumorigenic phenotype. In view of the evidence that many tumors
occurring in nature arise from the selection of cells with genetic
and/or epigenetic changes [3], one interpretation of our data is
that the in vitro passage of VERO cells selected for the expansion of
cells bearing alterations in the expression of specific miRNAs.
These findings lead us to propose that the miRNA signatures
identified in early-passage VERO cells (10-87 LP) and late-passage
VERO cells (10-87 HP and 10-87 T cells) were indicative of the
progressive changes in VERO cells that were undergoing
neoplastic transformation during serial passage in cell culture.
To determine whether the overexpression of the identified
signature miRNAs could increase the levels of cell migration or
invasion – phenotypes that correlated with the capacity to form
tumors in animals – stable cell lines expressing the pre-miRNA
sequences of some miRNAs were generated from the non-
tumorigenic 10-87 LP cells. These experiments demonstrated that
miR-376a and miR-376abc were sufficient to confer the cell
migration and invasion phenotype. No change in migration and
invasion phenotypes was observed in cells expressing miR-382 or
miR-299-5p. Recently, a target and function of miR-376a has
been identified. A human cytomegalovirus (HCMV) miRNA acts
synergistically with a cellular miR-376a to suppress one of the
major histocompatibility complex class I polypeptide-related
sequences (MICB) during HCMV infection [47]. The MICB is a
known ligand for natural killer cell activating receptor NKG2D,
which is over-expressed on cell surfaces after stress such as that
induced by viral infection and cell transformation [48,49]. It has
been documented that overexpression of microRNAs binding to
the MICB 39 UTRs results in enhanced tumorigenicity through
the downregulation of MICB expression, which enables tumors to
avoid immune recognition [47,48,49,50]. Furthermore, it was
found that NKG2D-mediated tumor rejection can be effective at
early stages of tumor growth [49,51,52,53]. While the specific
effect of miR-376a on tumorigenicity has not yet been demon-
strated, it is plausible to suggest that the 10-87 VERO cells might
use a similar mechanism as does HCMV to escape the immune
system during tumor growth in athymic nude mice.
When we compared experimental results from several published
studies on the differential expression of miRNA in different
cancers with our results, 30% (18 miRNAs) of the dysregulated
miRNAs identified in our study (Fig. 3) have an association with a
variety of other cancer types, including renal, prostate, lung,
bladder, breast, ovarian and retinoblastoma [16,34,41,42,4
4,45,46,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69]. When
compared with expression profiles of miRNAs associated with
renal cancer, there was a 15% overlap with the miRNAs described
in a recent report [54]; however, only miR-376a [67] out of the
highly upregulated miRNAs, and miR-638, miR-200b and miR-
200c from the highly downregulated miRNAs, were found to be in
common between our studies and other studies [67,70,71,72].
Although, there are differences in our in vitro model of neoplastic
development in VERO cells, which were derived from the kidney
of African green monkey, and tumors of the kidney that originated
in vivo in humans, the finding of similar patterns of dysregulation of
miRNAs in both systems suggests that similar molecular processes
may be underway during neoplastic development in cells from
both species irrespective of their microenvironments.
The other observation was the chromosomal clustering of the
genes for some of the miRNAs up-regulated in 10-87 HP cells.
Importantly, all of the genes for the 10 up-regulated miRNAs in
10-87 HP cells are clustered in a homologous chromosome
region of rhesus monkeys and humans. The genes for the 10
miRNAs highly expressed in 10-87 HP cells and 10-87 T cells are
spread over 47.6 kb on rhesus chromosome 7. This highly
conserved chromosomal region is homologous to human
14q32.31. Interestingly, specific up-regulation of some miRNAs
whose genes are located in the human 14q32 imprinted domain
has been reported in acute myeloid leukemia [37]. Clustering of
these miRNA genes suggests that their expression may be co-
regulated and that they might play a role in a common molecular
process. However, genes for some miRNAs included in the same
region did not show an increased expression in 10-87 HP cells,
suggesting a complex mechanism of gene regulation in this
region. It has been suggested that some miRNA genes in this
region act as tumor-suppressor genes and that changes in the
methylation status of their promoters can trigger cancer
development [36,37]. Furthermore, epigenetically regulated
expression of miRNA genes associated with oncogenic activity
has been described for some miRNAs [18,73,74]. Thus, it is
possible that the increased expression of some miRNAs but not
others in the cluster in 10-87 HP VERO cells could be due to
epigenetic changes within this chromosomal region. Another
possibility is that the altered level of mature miRNA could be due
to differential miRNA processing in 10-87 LP cells and 10-87 HP
cells, as reported in different stages of colorectal neoplasia [75].
Studies are being initiated to evaluate the mechanism of the
regulation of these miRNAs.
The phenomena of neoplastic development and neoplastic
transformation, whether they occur in vivo or in vitro, are thought
to represent the accumulation of a series of genetic and epigenetic
alterations that disrupt the norm a lp r o c e s s e so fc e l ld i v i s i o na n d
tissue integrity [1,2,3,4]. These processes convey upon the cells in
which they occur the propensity to outgrow unaffected cells and
either expand locally to produce tumor masses or spread and
gradually replace unaffected cells in tissue cultures. As these
genetic and epigenetic alterations accumulate, the affected cells
assume further growth advantages that allow them to invade
local tissues in their host or overgrow unaffected cells in vitro,a t
some point producing cells that form invasive tumors or cells that
possess the capacity to form tumors when injected into animals.
I nt h eV E R Oc e l lm o d e l ,w eh a v ef o u n dt h a tm i R N Ad o w n -
regulation occurs during the initial stages of neoplastic transfor-
mation that are associated with immortalization and some yet-to-
be defined forms of neoplastic progression that are not reflected
in a currently detectable phenotype by VERO cells at p140.
miRNA up-regulation occurs as the immortalized cells are
undergoing further neoplastic progression through the conver-
sion, during 116 passages (from p140 to p256) in cell culture, to
the expression of a tumorigenic phenotype. We have identified
miR-376a and the polycistronic miR-376abc as having a
functional role in establishing the enhanced cell migration and
cell invasion phenotypes, which are correlated with the
expression of the VERO cell tumorigenic phenotype. Studies
are underway to determine whether one or more of these over-
expressed miRNAs can confer on non-tumorigenic VERO cells
the capacity to form tumors in animals and consequently can be
used as biomarkers for the expression of the VERO-cell
tumorigenic phenotype.
The associations between neoplastic processes and miRNA
dysregulation in the VERO-cell model presented in this report
provide additional support for the concept that neoplastic
development in vitro and in vivo have similarities. If further
evidence for these similarities is forthcoming, the VERO-cell
model may provide a format for the systematic comparison of
neoplastic development in vivo and neoplastic transformation in vitro
across tissues, organs, and species.
miRNA and Neoplasia In Vitro
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14416Materials and Methods
Cell lines and cell culture
Cells from the World Health Organization (WHO) VERO cell
bank 10–87 (ATCC 10–87 VERO cells) were serially passaged in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10%
fetal bovine serum (FBS) (DMEM-10) from p134 to p250 by sub-
culturing VERO cells before they reached confluence [11]. For
the studies in this report, ATCC 10-87 VERO cells at p148 and
p256 were designated as low passage (10-87 LP) and high passage
(10-87 HP) VERO cells, respectively. A4497 VERO cells were
obtained from J.G. Tully, NIAID, and a cell bank was established
at p160. Serum-free (SF) VERO cells were provided by J. Weir
(DVP, OVRR, CBER); the passage level of this cell line is
unknown. BSC-1 and CV-1 cells were obtained from ATCC at
passage 43 and 34, respectively. The control cells were from 3
different lots (obtained from the kidneys from 3 different monkeys)
of pAMGK cells and were obtained from Diagnostic Hybrids
(Athens, Ohio). A cell line (10-87 T) was established from a tumor
formed in a newborn nude mouse following subcutaneous
inoculation of 10-87 HP cells [11]. The cells used in this study
were confirmed to be of simian origin by karyotyping (10-87 LP,
10-87 HP, and 10-87 T) and by PCR using primers that recognize
simian SINE sequences. The ability of these cells to form tumors in
vivo is summarized in Table 1.
Determination of cell-growth curves
Dishes (60 mm) were seeded with 5610
4 cells in DMEM-10.
The cells were trypsinized and counted in triplicate (using trypan-
blue exclusion to determine the number of viable cells) after 16,
24, 48, and 72 h in culture using a Cellometer (Nexcelom
Biosciences, Lawrence, MA). Growth curves of the VERO cells
were plotted from successive cell counts as described [76].
RNA extraction and qRT-PCR assays
Total RNA from pAGMK cells and the cell lines was extracted
and purified using the miRNeasy mini kit according to the
manufacturer’s procedures (Qiagen Inc., Valencia, CA). Taqman
miRNA assays (Applied Biosystems, Foster City, CA) were used to
quantify mature miRNA expression as described [77]. For miRNA
expression quantification, each reverse transcriptase (RT) reaction
volume of 20 mL consisted of 50 ng of purified total RNA, 16RT
buffer, dNTPs (each at 0.375 mM), 5 U/mL MultiScribe reverse
transcriptase, 50 nM stem-loop RT primers and 0.38 U/mL
RNase inhibitor (Applied Biosystems). RT reactions were
incubated at 16uC for 30 min, 42uC for 30 min and 85uC for
5 min. Real-time PCR amplifications were performed in triplicate
in 10-mL volumes. Quantitative miRNA expression data were
acquired and analyzed using an ABI Prism 7900 Sequence
Detection System (Applied Biosystems). Experiments were done in
triplicate and an average was calculated. Expression values were
normalized to a small nucleolar RNA, RNU6 (Applied Biosys-
tems). DCt values were calculated using the Ct values of the
miRNA probes and the RNU6 for each corresponding sample.
DDCt values are calculated using the DCt values of the pAGMK
cells and the experimental cell lines for each miRNA probe. The
fold change over pAGMK was calculated.
MicroRNA microarray assay
The microarray-expression assay was performed using a service
provider (LC Sciences, Houston, Texas). Because the genome
sequence of the African green monkey is not available, there are
no commercially available African green monkey miRNA chips. A
primate miRNA chip that contained all human and non-human
primate miRNA transcripts in the Sanger miRBase Release 10.0
was used (http://microrna.sanger.ac.uk/). Total RNA (4 to 8 mg)
was size fractionated using a YM-100 Microcon centrifugal filter
(Millipore, Billerica, MA), and the small RNAs (,300 nucleotides)
were isolated and 39 extended with a poly(A) tail using poly(A)
polymerase. An oligonucleotide tag was then ligated to the poly (A)
tail for later fluorescent-dye staining. Hybridization was performed
overnight on a mParaflo microfluidic chip using a micro-circulation
pump (Atactic Technologies, Houston, TX). The hybridization
buffer was 6xSSPE (0.90 M NaCl, 60 mM Na2HPO4,6 m M
EDTA, pH 6.8) containing 25% formamide at 34uC. On the
microfluidic chip, each detection probe consisted of a chemically
modified nucleotide-coding segment complementary to target
miRNA (http://microrna.sanger.ac.uk/sequences/) and a spacer
segment of polyethylene glycol to extend the coding segment away
from the substrate. The detection probes were made by in situ
synthesis using photogenerated reagent (PGR) chemistry. The
hybridization-melting temperatures were balanced by chemical
modifications of the detection probes. After RNA hybridization,
tag-conjugating Cy3 and Cy5 dyes were circulated through the
microfluidic chip for dye staining. Fluorescence images were
collected using a laser scanner (GenePix 4000B, Silicon Valley,
CA) and digitized using Array-Pro image analysis software (Media
Cybernetics, Bethesda, MD). Data were analyzed by first
subtracting the background and then normalizing the signals
using a LOWESS filter (Locally-weighted Regression) [78] to
balance the intensities of the Cy3- and Cy5-labeled transcripts so
that differential expression ratios can be calculated. The ratio of
the two sets of detected signals for each of the10-87 cells vs. the
pAGMK cells (log2 transformed, balanced) and p-values of the t-
test were calculated; differentially detected signals were those with
p,0.01. The expression patterns of unfiltered data (the raw data
from 654 miRNA data sets) were assessed using unsupervised
hierarchical clustering of samples based on average linkage and
Euclidian distance. When comparing two groups, the findings
were considered significant if: 1) the fold change was $4, 2) the t-
test, p-value was ,0.01, and 3) the difference in fluorescence
intensity between the two group means were .500 arbitrary units.
ANOVA was done between the four groups of cell lines. All
significantly expressed miRNAs with mean intensity value more
than 500 (arbitrary units) in at least in one of the four groups and a
p,0.01 were selected and transformed to z-intensity values for
inclusion in the heat-maps. The clustered heat-map was created in
TM4 microarray software (http://www.tm4.org) using the z-
transformed miRNA expression. The dendrogram along the rows
was calculated using 1-Pearson correlation for the distance
measure and complete linkage for the clustering algorithm.
Microarray data comply with MIAME requirements and have
been deposited at Gene Expression Omnibus data base (accession
number GPL10649).
Wound-healing assay
The wound-healing assay was carried out as described [31] with
minor modifications. Cells were seeded in 60-mm dishes (10
5
cells/dish). When the cultures reached 90% confluence, they were
serum starved for 8 h. After scratching the monolayer with a
pipette tip, cells were washed with PBS, cultured in DMEM-10,
and photographed under a 106 objective every 3 h for the first
15 h and then at 24 h.
Matrigel-invasion assay
The assay was performed as described [31] with minor
modifications. Cells (4610
4) in DMEM with 1% FBS (DMEM-
1) were placed in the upper chamber of a Biocoat Matrigel-
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was used as the chemoattractant in the lower chamber. After
incubation for 18 h at 37uC, the filters were stained with Diff-
Quick stain set (Dade Berhring Inc., Newark, DE), and the
number of cells that penetrated the Matrigel and the control insert
were counted with a microscope using a 206 objective (5
randomly selected fields).
Constructs and stable cell lines
The double-stranded oligonucleotides encoding the pre-miRNA
sequences of miR-376a, miR-299, miR-382 or irrelevant miRNA
(a miR-negative control, predicted not to target any known
vertebrate gene) were cloned into the pcDNA6.2-GW/EmGFP-
miR expression vector such that the pre-miRNA insertion site was
in the 39 untranslated (39UTR) region of the green fluorescent
protein (GFP) gene as per the instruction manual (Invitrogen,
Carlsbad, CA). The following oligonucleotides were used to
generate the pre-miRNAs: miR-376a sense, 59-tgctGTAAAAGG-
TAGATTCTCCTTCTATGAGTACATTATTTATGATTAAT-
CATAGAGGAAAATCCACGTTTTC-39 and miR-376a anti-
sense 59- cctgGAAAACGTGGATTTTCCTCTATGATTAAT-
CATAAATAATGTACTCATAGAAGGAGAATCTACCTTT-
TAC-39. miR-299-5p sense, 59- tgctGAAGAAATGGTTTAC-
CGTCCCACATACATTTTGAATATGTATGTGGGATGGT-
AAACCGCTTCTT-39 and miR-299-5p anti-sense 59-cctgAA-
GAAGCGGTTTACCATCCCACATACATATTCAAAATGT-
ATGTGGGACGGTAAACCATTTCTTC-39, miR-382 sense
59- tgctGTACTTGAAGAGAAGTTGTTCGTGGTGGATTC-
GCTTTACTTATGACGAATCATTCACGGACAACACTTT-
TTTCAGTA-39 and miR-382 anti-sense 59-cctgTACTGA-
AAAAAGTGTTGTCCGTGAATGATTCGTCATAAGTAAA-
GCGAATCCACCACGAACAACTTCTCTTCAAGTAC-39.
An expression plasmid for the polycistronic gene cluster for miR-
376a, miR-376b and miR-376c was generated by amplifying
200 bp up-stream and 200 bp down-stream of the genes (termed
as miR-376abc) in VERO cell DNA using primers 59-CC-
CTCGACGAGAGTGATGGAAGGTGAATC-39 and 59-CCA-
GATCTATACTGAGAACACAGCCTTGT-39. This PCR pro-
duct was digested with Sal I and Bgl II and cloned into the Sal I and
Bgl II sites of the digested pcDNA6.2-GW/EmGFP-miR expres-
sion vector in the 39 UTR region of GFP protein. The plasmids
were verified by sequencing across the insert. The expression
constructs were introduced into the non-tumorigenic 10-87 LP
cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Stable
cell lines that constitutively expressed the specific miRNAs were
selected using blasticidin (8 mg/mL). Blasticidin-resistant colonies
were identified after 15 days of selection. The stable cell lines were
sorted for high GFP expression using a BD FACSAria II (BD
Biosciences, San Jose, CA) and tracked using fluorescence
microscopy.
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